Soo, we have a lot of stuff now in the pipeline...seems like Oct-Jan timeframe is getting pretty full...
pls lemme know if I missed something- US FDA (Access Bio-AT1 AB test approval) (Oct?) + subsequent 77k device supply (Oct-Dec?) or more
- India (Divoc-AT1 AB test submission-approval (Oct-Dec)
- AU PDI (Access Bio-AT1 AB test review) (Nov-Dec?)
- PH, TW, HK (Access Bio-AT1 AB test submission-approval) (Oct-Jan?)
- AU, NZ, India (Access Bio-At1 AG test submission-approval) (Oct-Dec?)
- India (NG Biotech-AT1 AB test approval (Dec?)
+
- AT1 1.3m/mth scale-up done (by Jan)
+
- AT1 brand tests (AB first and then later AG) getting orders for AU market (Oct-Jan)?
- NG Biotech hopefully taking up remainder of their original order + asking more for EU (by Jan or anytime)?
- NG Biotech finishing antigen clinical trials (nasal, blood, Q4 2020) + hopefully partnering with AT1 device for blood (Jan?)
- Lumos Diagnostics finishing USA FebriDx clinical trials (Q4 2020) + hopefully ordering more for UK&I/EU markets (Q1 2021?)
+
Nov2020 AGM to prep for
....reckon more busy times now than even pre-IPO
@AT1 HQ...
